Streetbeat News

Stock Prices

BCPC

Balchem (NASDAQ:BCPC) is set to release its quarterly earnings report on October 25, 2024. Analysts expect an EPS of $1.11. The market is optimistic about Balchem surpassing estimates and providing positive guidance, which could drive stock prices. Historically, Balchem's EPS beats have not always led to immediate stock price increases.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

VRTS

Virtus Inv (NASDAQ:VRTS) is set to announce its quarterly earnings on October 25, 2024, with analysts estimating an EPS of $6.78. The company's past performance shows mixed results, with a recent EPS miss leading to a stable stock price. Analysts rate Virtus Inv as 'Underperform' with a slight potential upside. The company's financial metrics, such as revenue growth and return on equity, lag behind industry peers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

MNPR

Monopar Therapeutics shares have resumed trading, which could indicate a resolution of previous issues that halted trading.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 3:01 pm

SAIA

Saia (NASDAQ:SAIA) is set to release its quarterly earnings report on October 25, 2024. Analysts expect an EPS of $3.51. Investors are keen on the announcement, hoping for positive results and guidance. Saia's past performance shows mixed results with varying impacts on stock prices.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

GNTX

Gentex (NASDAQ:GNTX) is set to release its quarterly earnings on October 25, 2024. Analysts expect an EPS of $0.50. The market is optimistic about Gentex surpassing estimates and providing positive guidance. Historical performance shows mixed results, with a notable EPS miss last quarter.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

AVTR

Avantor (NYSE:AVTR) is set to announce its quarterly earnings on October 25, 2024, with analysts estimating an EPS of $0.25. The company's past performance shows mixed stock price reactions to earnings beats. Avantor's stock has risen 32.11% over the past year, and analysts have given it an 'Outperform' rating with a price target suggesting a 25.08% upside. Despite a slight decline in revenue growth, Avantor shows strong operational efficiency and profitability metrics compared to peers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

B

Barnes Gr (NYSE:B) is set to announce its quarterly earnings on October 25, 2024, with analysts estimating an EPS of $0.39. The company's past performance shows mixed results, with a recent EPS miss leading to a slight share price drop. Despite a 131.98% increase in share price over the last year, analysts have a Neutral rating with a slight downside in the price target. Barnes Gr faces challenges in revenue growth, profitability, and debt management compared to its peers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

CRI

Carter's (NYSE:CRI) is set to release its quarterly earnings on October 25, 2024. Analysts expect an EPS of $1.34. The company's past performance shows mixed results with a neutral analyst rating and a potential downside in stock price. Carter's has strong profitability metrics but faces challenges in revenue growth.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

AMZN

Amazon.com (NASDAQ:AMZN) has received diverse analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has slightly increased to $228.76. Analysts have maintained or adjusted their ratings and price targets based on market conditions and company performance. Amazon's financial metrics, such as revenue growth and net margin, are strong compared to industry averages.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

JNJ

The article provides a comparative analysis of Johnson & Johnson (JNJ) against its competitors in the Pharmaceuticals industry. JNJ shows potential undervaluation with lower PE, PB, and PS ratios compared to industry averages. However, it underperforms in ROE, EBITDA, gross profit, and revenue growth, indicating potential operational inefficiencies. Despite this, JNJ maintains a strong financial position with a lower debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm